Key opportunities in the GLP-1 Analogues market include surging demand due to escalating diabetes and obesity rates, enhanced drug innovations (e.g., oral formulations), and significant growth in ...

The "GLP-1 Analogues Market" report has been added to ResearchAndMarkets.com's offering. This report provides detailed information on glucagon-like peptide-1 (GLP-1) analogues. It analyzes market ...

Researchers map the peptide behind semaglutide across 25 brain regions in each sex, finding striking differences in ...

“GLP-1 analogues are reshaping diabetes and obesity care as innovation in drug delivery, expanding indications, and strong R&D pipelines drive explosive global demand.” Boston, Jan. 30, 2026 (GLOBE ...

This World Obesity Day, the conversation around weight is shifting. No longer just about willpower, obesity is recognised as a chronic disease. Breakthrough medications like GLP-1 analogues are ...

Eli Lilly LLY, a dominant player in the global obesity market, derives most of its revenues from its blockbuster GLP-1 medicines, Mounjaro for type II diabetes (T2D) and Zepbound for obesity. Despite ...

Researchers create the first sex-specific GLP-1 brain atlas, revealing why weight-loss drugs work differently in men and women.

LONDON & SAN FRANCISCO--(BUSINESS WIRE)--Verdiva Bio Limited (“Verdiva Bio” or “the Company”) a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and ...

Reductions in alcohol intake noted in high and low consumers; no significant difference seen in percentage reductions for men and women. (HealthDay News) — Glucagon-like peptide-1 receptor agonists ...